You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,384,081


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,384,081
Title: Treatment of diseases of the eye characterized by the formation of metalloproteinase
Abstract:The instant invention provides a method of inhibiting the formation of metalloproteinase and its species, within the eyes of a patient inflicted with at least one form of retinitis characterized by the presence of metalloproteinase, through the administration of an effective dosage that includes an a tetracycline analog, its salts, conjugates or derivatives. In an alternate preferred embodiment of the invention, the dosage includes at least one other therapeutic substance in effective combination with a tetracyline analog.
Inventor(s): Berman; Charles L. (New York, NY)
Assignee:
Application Number:09/169,660
Patent Claims:1. A method for treating retinitis in an eye of a patient wherein said retinitis is characterized by the presence of metaloproteinase comprising:

administering to said patient an antibacterial or non-antibacterial analog of tetracycline, its salts, conjugates, or derivatives or combinations thereof in a dosage amount effective to prohibit the further formation of said metaloproteinase, said metaloproteinase being a member selected from the group consisting of collagenase, elastase and gelatinase and combinations thereof.

2. The method of claim 1 wherein said retinitis is a disease of the eye selected from the group consisting of actinic retinitis, apoplectic retinitis, central angioplastic retinitis, centralis serious retinopathy, Coat's retinitis, exudative retinopathy, diabetic retinitis, retinitis disciformans, exudate retinitis, retinitis gravitdarum, hemorrthagica retinitis, hypertensive retinitis, Jacobson's retinitis, leukemic retinitis, retinitis nephritica, renal retinitis, retinitis pigmentosa, retinitis proliferans, proliferating retinitis, retinitis putata albescerns, punctate retinitis, renal retinitis, nepritica, serous retinitis, solar retinitis, splenic retinitis, retinitis stellata, supporative retinitis, syplititic retinitis, retinitis syphlitica, remic retinitis, retinal microvasculopathy, cytomegalovirus retinitis, Herpes simplex retinitis, acute retinal necrosis, Herpes zoster retinitis and Toxoplasma retinochoroditis.

3. The method of claim 1 wherein said tetracycline analog is an antibacterial tetracycline, a non-antibacterial tetracycline or combinations thereof and is a member selected from the group consisting of dedimethylaminotetracycline, 4-dedimethylamino5-oxytetracycline, 4-dedimethylamino-7-chlorotetracycline, 5-alpha-6-anhydro-4-hydroxy-4-dedimethylaminotetracycline, 6-demethyl-6-deoxy-4-dedimethylaminotetracycline, 6-alpha-deoxy-5-hydroxy-4-dedimethylaminotetracycline, 4-dedimethylamino-12-alpha-deoxytetracycline, 4-dedimethylamino-11-hydroxy-12-alpha-deoxytetracycline, minocycline, doxycycline, 7-chlorotetracycline, 5-hydroxytetracycline, 6-demethyl-7-chlorotetracycline, 6-demethyl-6-deoxy-5-hydroxy-6-methylenetetracycline, 6-alpha-benzylthiomethylenetetracycline, mono-N-alkylated amide of tetracycline, 6-fluorodemethyltetracyclune, 11-alpha-chlorotetracycline, tetracyclinonitrile, tetracycline hydrochloride, oxyteracycline, chlorotetracycline, 7-chloro-6-demethyl-4-dedimethylaminotetracycline, 2-alpha-deoxy-4-deoxy-4-dedimethylaminotetracycline, 12-alpha-4-alpha-anhydro-4-dedimethylaminotetracycline, 7-dimthylamino-6-demeyhl-6deoxy-4-dedimethylaminotetracycline, tetracycline pyrazole, 6alpha-deoxy-5-hydroxy-4-dedimethylaminotetracycline, 12-alpha-deoxytetracycline, methyacycline, their salts, conjugates or derivatives and combinations thereof.

4. The method of claim 1 wherein said tetracycline analog is administered in a dosage amount of from about 0.1 to about 100 mg/kg/day.

5. The method of claim 4 wherein said dosage amount is from about 10 to about 50 mg/kg/day.

6. The method of claim 4 wherein said dosage amount is from about 20 to about 25 mg/kg/day.

7. The method of claim 1 wherein said tetracycline analog is administered orally, systemically, topically, intravenously or by injection.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.